Compare ECPG & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ECPG | NVAX |
|---|---|---|
| Founded | 1998 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 1999 | 1995 |
| Metric | ECPG | NVAX |
|---|---|---|
| Price | $55.21 | $6.82 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 8 |
| Target Price | ★ $59.50 | $9.75 |
| AVG Volume (30 Days) | 241.6K | ★ 3.2M |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 2.07 |
| Revenue | ★ $1,560,869,000.00 | $1,064,651,000.00 |
| Revenue This Year | $32.56 | $58.91 |
| Revenue Next Year | $3.04 | N/A |
| P/E Ratio | ★ N/A | $3.29 |
| Revenue Growth | 17.52 | ★ 20.27 |
| 52 Week Low | $26.45 | $5.01 |
| 52 Week High | $56.67 | $11.55 |
| Indicator | ECPG | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 64.12 | 48.21 |
| Support Level | $53.95 | $6.36 |
| Resistance Level | $55.72 | $7.00 |
| Average True Range (ATR) | 1.48 | 0.21 |
| MACD | -0.20 | 0.07 |
| Stochastic Oscillator | 63.72 | 71.88 |
Encore Capital Group Inc is an international specialty finance company. It provides debt recovery solutions for consumers and property owners across a broad range of financial assets. The company purchases portfolios of defaulted consumer receivables at deep discounts to face value and manages them by working with individuals as the consumers repay their obligations and work toward financial recovery. Encore has only a reportable segment portfolio purchasing and recovery.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.